The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced new data from studies of VOXZOGO® (vosoritide)

BioMarin stock climbed after Phase 3 VOXZOGO data showed significant growth improvements in children

B of A Securities analyst Jason Zemansky maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a B

Citigroup analyst Eric Joseph initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

ENERGY 3 is a Phase 3 multicenter randomized (2:1) controlled open-label clinical trial designed to

Goldman Sachs analyst Salveen Richter reinstates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neu

Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy

Bernstein analyst William Pickering maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outper

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Ov

RBC Capital analyst Luca Issi reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perf

Evercore ISI Group analyst Cory Kasimov maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Ou

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMR

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over

https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000119312526173770/d139584d8k.htm

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that the Board of Directors has appointed Ian

Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strengt

New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skele

Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page

B of A Securities analyst Geoff Meacham maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Bu

BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory fili

Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight a

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMR

The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12

Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy

Bernstein analyst William Pickering maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outper

Guggenheim analyst Debjit Chattopadhyay maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Bu

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outper

BioMarin Pharmaceutical (NASDAQ:BMRN) sees FY2026 sales of $3.325 billion-$3.425 billion vs $3.507 b

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.46 per share which missed th

Wells Fargo analyst Mohit Bansal maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweigh

BridgeBio stock rises after Phase 3 trial shows its drug helped children with achondroplasia grow fa

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Over

BioMarin also announced that, in connection with the pending acquisition (the "Acquisition")

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to

Canaccord Genuity analyst Whitney Ijem upgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Hold t

Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovat

Rocket Lab, Micron, Sandisk, and CoreWeave led last week's large-cap rally—alongside Lumentum, V

US stocks edged higher midday Wednesday after strong Q3 GDP data. In commodities, both silver and go